184 related articles for article (PubMed ID: 14715107)
1. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer.
Spigel DR; Burstein HJ
Clin Breast Cancer; 2003 Dec; 4(5):329-37; discussion 338-9. PubMed ID: 14715107
[TBL] [Abstract][Full Text] [Related]
2. HER2 overexpressing metastatic breast cancer.
Spigel DR; Burstein HJ
Curr Treat Options Oncol; 2002 Apr; 3(2):163-74. PubMed ID: 12057079
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
4. Maximizing clinical benefit with trastuzumab.
Bell R; Verma S; Untch M; Cameron D; Smith I
Semin Oncol; 2004 Oct; 31(5 Suppl 10):35-44. PubMed ID: 15490373
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-based combinations in metastatic breast cancer: how to make a choice.
Jahanzeb M
Clin Breast Cancer; 2003 Apr; 4(1):28-38. PubMed ID: 12744756
[TBL] [Abstract][Full Text] [Related]
6. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
7. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
Pegram MD; O'Callaghan C
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S15-9. PubMed ID: 11970740
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-based combination therapy for breast cancer.
Montemurro F; Valabrega G; Aglietta M
Expert Opin Pharmacother; 2004 Jan; 5(1):81-96. PubMed ID: 14680438
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
[TBL] [Abstract][Full Text] [Related]
10. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin).
Nabholtz JM; Slamon D
Semin Oncol; 2001 Feb; 28(1 Suppl 3):1-12. PubMed ID: 11301369
[TBL] [Abstract][Full Text] [Related]
11. Her2 and trastuzumab in breast cancer.
Horton J
Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040
[No Abstract] [Full Text] [Related]
12. Sensitization of chemotherapy by anti-HER.
Kataoka A; Ishida M; Murakami S; Ohno S
Breast Cancer; 2004; 11(2):105-15. PubMed ID: 15550854
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ; Press M
J Clin Oncol; 2002 Feb; 20(3):719-26. PubMed ID: 11821453
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
16. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
17. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
18. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
19. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
Lin A; Rugo HS
Curr Treat Options Oncol; 2007 Feb; 8(1):47-60. PubMed ID: 17660958
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]